NewcelX Ltd.
$2.83
▼
-4.04%
2026-04-21 08:21:01
newcelx.com
NCM: NCEL
Explore NewcelX Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.13 M
Current Price
$2.83
52W High / Low
$30.8 / $1.83
Stock P/E
—
Book Value
$-11.28
Dividend Yield
—
ROCE
23.66%
ROE
158.49%
Face Value
—
EPS
$-6.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
11
Beta
0.57
Debt / Equity
-0.97
Current Ratio
0.02
Quick Ratio
0.09
Forward P/E
—
Price / Sales
—
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
| 2. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 3. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 4. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 5. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 6. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 7. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -6.9 M | -11.04 M | -22.01 M | -24.3 M |
| Net Profit | -26.55 M | -12.01 M | -22.72 M | -26.27 M |
| EPS in Rs | -5.82 | -2.63 | -4.98 | -5.76 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 3.3 M | 8.37 M | 12.49 M | 27.34 M |
| Total Liabilities | 32.44 M | 12.73 M | 12.16 M | 11.96 M |
| Equity | -29.15 M | -4.36 M | 0.33 M | 15.38 M |
| Current Assets | 2.85 M | 5.79 M | 7.42 M | 23.98 M |
| Current Liabilities | 32.44 M | 12.71 M | 10.53 M | 11.18 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -2.75 M | -11.09 M | -20 M | -21.55 M |
| Investing CF | 0.6 M | 0.33 M | -0.66 M | -0.38 M |
| Financing CF | 0.38 M | 8.59 M | 3.72 M | 39.8 M |
| Free CF | -2.78 M | -11.11 M | -20.64 M | -22.08 M |
| Capex | -0.02 M | -0.02 M | -0.64 M | -0.54 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -121.1% | 47.14% | 13.54% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-10-31 | 1:0.1 |
| 2024-09-27 | 1:0.025 |